Late Tuesday afternoon, the companies presented mediocre trial results showing that bapineuzumab (b-mab for short) didn't work overall in an 18-month second stage trial but seemed to help a subset of patients who lack a certain gene mutation, APOE4.

FORBES: Magazine Article